Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Investment Securities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Gains from Investment Securities for 14 consecutive years, with $12000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 101.13% to $12000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$691000.0 through Dec 2025, down 123.21% year-over-year, with the annual reading at $29.2 million for FY2025, 1.9% up from the prior year.
  • Gains from Investment Securities hit $12000.0 in Q4 2025 for Coherus Oncology, up from $3415.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.8 million in Q1 2023 to a low of -$1.1 million in Q4 2024.
  • Historically, Gains from Investment Securities has averaged $520169.6 across 5 years, with a median of $234500.0 in 2021.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 3582.61% in 2022 and later crashed 212.42% in 2024.
  • Year by year, Gains from Investment Securities stood at $23000.0 in 2021, then surged by 3582.61% to $847000.0 in 2022, then rose by 11.22% to $942000.0 in 2023, then plummeted by 212.42% to -$1.1 million in 2024, then soared by 101.13% to $12000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for CHRS at $12000.0 in Q4 2025, $3415.0 in Q3 2025, and $43000.0 in Q2 2025.